Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

MD Anderson study sheds light on miR569 gene

A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.

9 Dec 2014

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan.

4 Dec 2014

Oncolytics Biotech submits Orphan Drug Designation for pancreatic, ovarian cancers

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted applications for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of pancreatic and ovarian cancers.

2 Dec 2014

Faster and more accurate method for testing new cancer drugs

Finding faster and more accurate ways to test new cancer drugs is always a priority for cancer researchers.

2 Dec 2014

Cedars-Sinai Medical Center releases November tip sheet of story ideas

Following is the November 2014 tip sheet of story ideas from Cedars-Sinai Medical Center.

27 Nov 2014

Pathology specialist publishes invited commentary on breast cancer gene screening

There has been much recent debate on the benefits and risks of screening for breast cancer using BRCA1 and BRCA2 mutations in the general adult population.

27 Nov 2014

Surprise WHI finding points to age, not menopause, as a risk factor for pelvic organ prolapse

Removing ovaries at hysterectomy does not increase a woman's risk of pelvic organ prolapse after menopause. In fact, removing ovaries lowers the risk of prolapse. This surprising finding from a Women's Health Initiative study was published online this week in Menopause, the journal of The North American Menopause Society.

27 Nov 2014

New Sophia DDM platform offers full BRCA1/2 analysis on a single NGS run

Sophia Genetics, the European leader in Clinical Genomics and Next Generation DNA Sequencing (NGS), has today launched a major upgrade to its Data Driven Medicine Platform (Sophia DDM), offering full BRCA1/2 analysis on a single NGS (Next Generation Sequencing) run, for the first time.

26 Nov 2014

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

PharmaMar announces that Janssen Research & Development, LLC has submitted a New Drug Application (NDA) for YONDELIS (trabectedin) to the U.S. Food and Drug Administration for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.

26 Nov 2014

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Testosterone (T) therapy is routinely used in men with hypogonadism, a condition in which diminished function of the gonads occurs. Although there is no evidence that T therapy increases the risk of prostate cancer (PCa), there are still concerns and a paucity of long-term data.

25 Nov 2014

TapImmune signs new collaborative research agreement with VGTI Florida

TapImmune, Inc., is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida, a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.

18 Nov 2014

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy - and they also have a lower survival rate than those who are non-carriers of these genetic mutations. Data from the study, which has been published in the journal European Urology, points to the need for new clinical trials aimed at targeting these mutations in order to tailor treatment for these patients.

17 Nov 2014

Chemotherapy drug combined with cancer-killing virus may treat recurrent ovarian cancer

In six out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and five-year survival is only 27 percent.

14 Nov 2014

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

In a potential breakthrough against ovarian cancer, University of Guelph researchers have discovered how to both shrink tumours and improve drug delivery, allowing for lower doses of chemotherapy and reducing side effects.

13 Nov 2014

RPCI researchers identify two novel candidate prognostic markers for ovarian cancer

Cancer researchers at Roswell Park Cancer Institute have identified two independent classes of novel candidate prognostic markers for ovarian cancer, advancing efforts to develop targeted therapies for the disease. The findings resulted from two separate studies published in the peer-reviewed journal PLoS ONE and based on data from The Cancer Genome Atlas (TCGA), the world's largest public database on gene expression in different tumor types.

12 Nov 2014

Cigarette smoking increases risk of developing second smoking-associated cancer

Results of a federally-funded pooled analysis of five prospective cohort studies indicate that cigarette smoking prior to the first diagnosis of lung (stage I), bladder, kidney or head and neck cancer increases risk of developing a second smoking-associated cancer. This is the largest study to date exploring risk of second cancers among current smokers.

11 Nov 2014

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.

7 Nov 2014

Dr. Grace Campbell receives RNF Fellow Research Grant Award

The Rehabilitation Nursing Foundation (RNF) presents Dr. Grace Campbell, PhD BSN RN CRRN MSW, with the RNF Fellow Research Grant Award. RNF offers $30,000 in the form of multiple grants for research projects that address the clinical practice, educational or administrative dimensions of rehabilitation nursing. Dr. Campbell received her award at the ARN 40th Annual Educational Conference, October 29 - November 1, 2014 in Anaheim, CA.

5 Nov 2014

People with lactose intolerance at lower risk of suffering from certain cancers

People with lactose intolerance are at lower risk of suffering from lung, breast and ovarian cancers, according to a new study by researchers at Lund University and Region Skåne in Sweden.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

MD Anderson study sheds light on miR569 gene

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Oncolytics Biotech submits Orphan Drug Designation for pancreatic, ovarian cancers

Faster and more accurate method for testing new cancer drugs

Cedars-Sinai Medical Center releases November tip sheet of story ideas

Pathology specialist publishes invited commentary on breast cancer gene screening

Surprise WHI finding points to age, not menopause, as a risk factor for pelvic organ prolapse

New Sophia DDM platform offers full BRCA1/2 analysis on a single NGS run

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

TapImmune signs new collaborative research agreement with VGTI Florida

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Chemotherapy drug combined with cancer-killing virus may treat recurrent ovarian cancer

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

RPCI researchers identify two novel candidate prognostic markers for ovarian cancer

Cigarette smoking increases risk of developing second smoking-associated cancer

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Dr. Grace Campbell receives RNF Fellow Research Grant Award

People with lactose intolerance at lower risk of suffering from certain cancers

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in